Oncotelic Therapeutics (OTCQB: OTLC) announced its placement in an editorial published by BioMedWire, one of more than 75 brands within the InvestorBrandNetwork. The article, titled “Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development,” highlights growing pharmaceutical interest in clinical-stage assets supported by human data and features Oncotelic as an example of a diversified clinical-stage company. The editorial notes the company’s recently expanded international intellectual property coverage for OT-101, its proprietary TGF-β antisense therapeutic platform, strengthening protection across neurology, oncology and CNS drug-delivery technologies designed to cross the blood–brain barrier.
NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://nnw.fm/OTLC
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer